CD19 and acute lymphoblastic leukemia: A clinical trial at Memorial Sloan‐Kettering Cancer Center in 2016 (NCT01044069) showed that 91% of 32 B cell‐derived acute lymphoblastic leukaemia (B‐ALL) patients treated with CD19‐targeted CAR‐T cells achieved complete remission.